NOVAVAX INC Current Assets
NOVAVAX INC (NVAX) had Current Assets of $771.10 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-06
- 2026-06-30: Assets, Current $771.10M.
- 2026-03-31: Assets, Current $850.82M.
- 2025-12-31: Assets, Current $978.28M.
- 2025-09-30: Assets, Current $974.59M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $771.10M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $850.82M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $978.28M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $974.59M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $919.51M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $868.03M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.13B 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.10B 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.20B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $727.12M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $1.14B 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.01B 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.13B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $971.03M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.70B 10-K · filed 2024-02-28 |
| 2022-09-30 | $1.76B 10-Q · filed 2022-11-09 |
| 2022-06-30 | $2.14B 10-Q · filed 2022-08-09 |
| 2022-03-31 | $2.35B 10-Q · filed 2022-05-10 |
| 2021-12-31 | $2.16B 10-K · filed 2023-02-28 |
| 2021-09-30 | $2.17B 10-Q · filed 2021-11-05 |
| 2021-06-30 | $2.35B 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.25B 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.25B 10-K · filed 2022-03-01 |
| 2020-09-30 | $671.22M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $636.38M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $255.23M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $97.25M 10-K · filed 2021-03-01 |
| 2019-09-30 | $89.02M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $110.22M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $123.39M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $119.28M 10-K · filed 2020-03-11 |
| 2018-09-30 | $160.54M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $194.34M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $181.03M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $203.31M 10-K · filed 2019-03-18 |
| 2017-09-30 | $226.00M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $236.68M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $258.45M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $287.83M 10-K · filed 2018-03-14 |
| 2016-09-30 | $353.90M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $419.98M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $484.60M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $287.26M 10-K · filed 2017-02-27 |
| 2015-09-30 | $310.10M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $332.98M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $350.09M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $188.16M 10-K · filed 2016-02-29 |
| 2014-09-30 | $191.98M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $166.60M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $128.87M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $145.00M 10-K · filed 2015-02-27 |
| 2013-09-30 | $155.02M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $45.37M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $51.72M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $50.41M 10-K · filed 2014-03-12 |
| 2012-09-30 | $36.48M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $34.98M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $26.44M 10-Q · filed 2012-05-09 |
| 2011-12-31 | $26.11M 10-K · filed 2013-03-12 |
| 2011-09-30 | $26.25M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $28.42M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $33.34M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |